Speakers from the world's largest organizations will share their needs and experiences with many world first announcements. Learn of the requirements and case studies from end users and hear all about the latest innovations from companies across the value chain.
Non-Invasive Biochemical Sensing: Breakthrough For Precision Medicine
Santa Clara Convention Center, CA, USA
Conference Room E
09:40 - 10:00
Today's non-invasive electronic health patches perform conventional measures like heart activity and body motion, while the medical field waits for continuous wearable sensing of chemical information like that found in blood draws. All this is now rapidly changing as sweat biosensing is targeting a first killer application in medication monitoring.
Gavi Begtrup, Ph.D. is the Chief Executive Officer of Eccrine Systems, Inc., a platform biotechnology company focused on enabling precision dosing through measurement of individual drug responses in eccrine sweat. Dr. Begtrup previously founded and was CEO of an agricultural materials startup and has supported technology commercialization and startup formation for research organizations and venture investment. Dr. Begtrup is an expert in micro- and nano-electromechanical systems, is the author of popular and scientific articles, and is an inventor on multiple issued and pending patents for novel nanoscale devices and sweat sensing systems. Prior to a career in technical entrepreneurship, Dr. Begtrup was the Policy Advisor for Congresswoman Gabrielle Giffords developing legislation in oversight of NASA, DOD, and other federal agencies. He also served as science and technology policy fellow at the National Academies of Science. Dr. Begtrup received his Ph.D. in Physics from the University of California, Berkeley and his B.S. from Western Kentucky University.
In developing the future of precision medicine, Eccrine is focused on closing the gap between population-based dosing protocols and individual drug response influenced by lifestyle, environment, and genetics. Eccrine Systems' personal drug response profiles will enable prescribers to optimize pharmacotherapy — helping to solve a $500B/year problem for U.S. healthcare. Using data insights derived from our medication monitoring platform, we are pioneering the field of Pharmacoeccrinology -- The study of personal drug response derived from the non-invasive and continuous measurement of drug and biomarker levels excreted in locally stimulated sweat.